Introducing Gene2Rx Recreational Substance Pharmacogenetics

New in-report genetics insights for alcohol, caffeine, nicotine, THC, ketamine, LSD, and MDMA

People often notice that the same substance can feel very different from one person to the next. One person can drink coffee late and sleep fine, while another gets jittery after half a cup. Some people flush after a single alcoholic drink. Others experience unusually strong or prolonged effects from cannabis products.

A major reason for this variability is pharmacogenetics (PGx): inherited differences in the genes that influence how your body processes a substance (pharmacokinetics) and how your brain and body respond to it (pharmacodynamics).

For many prescription medications, PGx recommendations are curated by consensus guideline groups or reflected in official labeling. For widely used recreational substances, the evidence supporting genetic effects is often strong, but formal, consensus guidelines frequently do not exist. This is largely because these substances sit in a therapeutic gray area.

To close that gap, we added a set of recreational substance pharmacogenetics to the Gene2Rx report and created our first in-house, curated guidance. These recommendations are intended to help customers understand common response patterns, identify potential higher-risk genetic profiles, and support better conversations with clinicians when relevant.

Important note: This content is educational. It is not medical advice and it is not intended to be used to make medication changes without a qualified healthcare professional.

What’s new in the report

We currently include:

Each page includes: - A plain-language overview - The most relevant genes - A summary of the evidence base - Our Gene2Rx guidance, including phenotype-based interpretation where possible

Why create Gene2Rx guidance for recreational substances?

For these substances, the field often has: - Clear biological mechanisms (how specific genes change metabolism or sensitivity) - Human pharmacokinetic data in many cases - Observational evidence linking genotype to outcomes such as intensity, duration, adverse effects, or dependence risk

But formal prescribing guidelines are limited or absent because many of these substances are not used in a standard therapeutic prescribing framework.

Our approach is to be transparent: - When evidence is strong, we say so - When evidence is promising but mixed or early, we label it accordingly - Guidance is presented as a way to interpret risk and response trends, not as a guarantee

How to interpret this section

Across these substances, Gene2Rx focuses on two complementary questions:

  1. How quickly do you clear the substance?
    Genetic variation in metabolizing enzymes can change exposure, half-life, and peak levels.

  2. How sensitive might your nervous system be to it?
    Genetic variation in receptors and signaling pathways can affect intensity, adverse effects, and vulnerability in certain contexts.

Genetics is rarely the only reason a substance feels strong or weak. Dose, route of administration, co-use with other substances, sleep, stress, medications, liver function, and individual tolerance can dominate real-world outcomes.

Substance-by-substance overview

Alcohol (Ethanol): acetaldehyde biology you can feel

Key genes: ADH1B, ALDH2
Core concept: acetaldehyde formation vs acetaldehyde clearance

Alcohol metabolism is dominated by a two-step pathway: - ADH1B converts ethanol to acetaldehyde - ALDH2 converts acetaldehyde to acetate

Some ADH1B variants can speed acetaldehyde formation. Some ALDH2 variants can dramatically reduce acetaldehyde clearance. The result can be high acetaldehyde exposure, which is associated with flushing, rapid heartbeat, nausea, and strong aversive effects in many people.

Why this is actionable: the mechanism is well established and the clinical phenotype is often obvious. A strong flush reaction is not just uncomfortable, it can be a biological marker of acetaldehyde exposure.

Learn more: https://gene2rx.com/drugs/alcohol/

Caffeine: why coffee “hits” differently

Key gene: CYP1A2
Core concept: fast vs slow clearance changes intensity and duration

Caffeine clearance is dominated by CYP1A2. Differences in CYP1A2 activity can lead to large differences in caffeine half-life. This can help explain why some people can tolerate caffeine later in the day, while others get insomnia, palpitations, or anxiety even at modest doses.

Gene2Rx guidance translates CYP1A2 phenotype into practical, safety-oriented suggestions, including timing and total daily intake concepts.

Learn more: https://gene2rx.com/drugs/caffeine/

Nicotine: metabolism, dependence biology, and cessation response

Key genes: CYP2A6, CHRNA5, COMT
Core concept: clearance affects exposure, receptor biology affects reinforcement and dependence risk

Nicotine response is shaped by both pharmacokinetics and pharmacodynamics:

This set is especially useful because it can connect genetics to both subjective response and real-world outcomes like dependence risk and response to cessation strategies.

Learn more: https://gene2rx.com/drugs/nicotine/

THC: exposure plus sensitivity

Key genes: CYP2C9 (metabolism), FAAH (endocannabinoid tone), AKT1 and COMT (risk and sensitivity signals)
Core concept: slower clearance can prolong effects, and neurobiology variants may affect vulnerability in some people

THC response varies widely. A core pharmacokinetic signal is CYP2C9: reduced-function variants can slow THC clearance and increase exposure, potentially leading to stronger or longer effects.

Additional genes are included because they influence pathways plausibly connected to reward, craving, and psychotomimetic sensitivity. Evidence quality varies, so Gene2Rx labels this section as exploratory and subject to refinement.

Learn more: https://gene2rx.com/drugs/thc/

Ketamine: a clearer metabolic signal

Key gene: CYP2B6
Core concept: slower clearance can prolong effects and increase adverse effects risk

Ketamine is used clinically in anesthesia and in some settings for depression care, and it is also used non-medically. The best-supported PGx signal here is CYP2B6, a key pathway for ketamine metabolism.

Reduced CYP2B6 function can be associated with higher exposure and prolonged effects in some studies. Gene2Rx guidance focuses on interpretation of metabolic capacity and emphasizes caution and monitoring concepts when relevant.

Learn more: https://gene2rx.com/drugs/ketamine/

LSD: CYP2D6 and exposure duration

Key gene: CYP2D6
Core concept: reduced CYP2D6 function can increase exposure and prolong effects

Human pharmacogenetic data suggests CYP2D6 phenotype can meaningfully change LSD exposure and duration. This is one of the reasons it was selected for inclusion, even though formal consensus guidelines are not available.

Gene2Rx guidance is explicitly positioned as inferential and evidence-driven rather than a consensus guideline.

Learn more: https://gene2rx.com/drugs/lsd/

MDMA: metabolism signals with a risk framing

Key genes: CYP2D6, COMT
Core concept: CYP2D6 can influence exposure, and signaling genes may shift sensitivity in some contexts

MDMA shows pharmacogenetic signal in controlled studies, particularly related to CYP2D6 and exposure differences. Interpretation is complicated by the fact that MDMA can inhibit CYP2D6 after dosing, which can reduce phenotype differences over time.

Gene2Rx includes MDMA because the evidence supports meaningful inter-individual variability tied to genetics, and because risk-relevant outcomes can be severe. The guidance is cautious, emphasizes uncertainty where appropriate, and is designed for education and harm-awareness.

Learn more: https://gene2rx.com/drugs/mdma/

What this update is meant to do for customers

This module is intended to help with: - Explaining patterns you already observe, like caffeine sensitivity or alcohol flush - Highlighting potentially higher-risk genetic profiles, especially when genetics plausibly increases exposure or adverse effects risk - Providing a structured, science-based way to discuss these topics with a clinician when relevant

As with the rest of Gene2Rx, we aim to update guidance as the evidence evolves.